New York State approves Eurofins Viracor new kidney transplant rejection biomarker test
Eurofins Viracor and Transplant Genomics stated that the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) has approved the company's Viracor TRAC donor-derived cell-free DNA test and TruGraf gene expression test, for use to
Eurofins Viracor and Transplant Genomics stated that the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) has approved the company's Viracor TRAC donor-derived cell-free DNA test and TruGraf gene expression test to assess the rejection status of kidney transplant recipients.
The company stated that it has obtained a dedicated Proprietary Laboratory Analyses (PLA) code for this test through the American Medical Association's current Procedural Terminology system (CPT®). Viracor TRAC is a non-invasive testing method based on the novel rejection biomarker—donor-derived cell-free DNA—that can detect early kidney transplant rejection. TruGraf is a gene expression test that also gives clinicians the possibility to detect subclinical rejection, because immune system expression changes are activated before indicative rejection occurs.
This means that kidney transplant patients in all 50 states, including New York, can use TRAC and TruGraf for rejection testing.
Some original figures, videos and downloadable materials are provided in Chinese.